Verdence Capital Advisors LLC Gilead Sciences, Inc. Transaction History

Verdence Capital Advisors LLC

$1.23 Billion
Q3 2024

A detailed history of Verdence Capital Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Verdence Capital Advisors LLC holds 26,699 shares of GILD stock, worth $2.44 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

26,699

Previous 23,438 13.91%

Holding current value

$2.44 Million

Previous $1.61 Million 39.12%

% of portfolio

0.18%

Previous 0.15%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$66.59 - $83.99 $217,149 - $273,891	3,261 Added 13.91%	26,699 $2.24 Million
Q2 2024 Jul 25, 2024	BUY	$63.15 - $72.88 $184,966 - $213,465	2,929 Added 14.28%	23,438 $1.61 Million
Q1 2024 Apr 25, 2024	BUY	$71.58 - $87.29 $518,883 - $632,765	7,249 Added 54.67%	20,509 $1.5 Million
Q4 2023 Jan 31, 2024	SELL	$73.27 - $83.09 $12,162 - $13,792	-166 Reduced 1.24%	13,260 $1.07 Million
Q3 2023 Oct 25, 2023	BUY	$73.94 - $80.67 $152,981 - $166,906	2,069 Added 18.22%	13,426 $1.01 Million
Q2 2023 Jul 28, 2023	SELL	$76.01 - $86.7 $321,294 - $366,480	-4,227 Reduced 27.12%	11,357 $875,000
Q1 2023 Apr 24, 2023	SELL	$77.31 - $88.08 $722,539 - $823,195	-9,346 Reduced 37.49%	15,584 $1.29 Million
Q4 2022 Jan 20, 2023	SELL	$62.32 - $89.47 $232,578 - $333,902	-3,732 Reduced 13.02%	24,930 $0
Q3 2022 Nov 15, 2022	BUY	$59.54 - $68.01 $89,607 - $102,355	1,505 Added 5.54%	28,662 $1.77 Million
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $30,303 - $34,130	525 Added 1.97%	27,157 $1.68 Million
Q1 2022 May 02, 2022	BUY	$57.92 - $72.58 $310,103 - $388,593	5,354 Added 25.16%	26,632 $1.58 Million
Q4 2021 Jan 26, 2022	BUY	$64.88 - $73.64 $45,416 - $51,548	700 Added 3.4%	21,278 $1.55 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $33,371 - $36,003	493 Added 2.45%	20,578 $1.44 Million
Q2 2021 Aug 06, 2021	BUY	$63.47 - $69.35 $152,708 - $166,856	2,406 Added 13.61%	20,085 $1.38 Million
Q1 2021 May 11, 2021	BUY	$60.0 - $68.46 $669,120 - $763,465	11,152 Added 170.86%	17,679 $1.14 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $328,853 - $374,712	-5,805 Reduced 47.07%	6,527 $380,000
Q3 2020 Nov 09, 2020	BUY	$62.1 - $78.08 $419,671 - $527,664	6,758 Added 121.24%	12,332 $779,000
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $664,081 - $771,120	-9,180 Reduced 62.22%	5,574 $429,000
Q1 2020 May 13, 2020	BUY	$62.63 - $80.22 $92,253 - $118,164	1,473 Added 11.09%	14,754 $1.1 Million
Q4 2019 Feb 03, 2020	SELL	$61.62 - $67.78 $42,825 - $47,107	-695 Reduced 4.97%	13,281 $863,000
Q3 2019 Mar 06, 2020	BUY	$62.51 - $69.0 $873,639 - $964,344	13,976 New	13,976 $886,000
Q2 2018 Feb 11, 2020	SELL	$64.88 - $75.68 $303,249 - $353,728	-4,674 Closed	0 $0
Q1 2018 Jan 30, 2020	SELL	$72.84 - $88.8 $251,370 - $306,448	-3,451 Reduced 42.47%	4,674 $352,000
Q4 2017 Jan 30, 2020	BUY	$71.15 - $83.52 $578,093 - $678,600	8,125	8,125 $582,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verdence Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verdence Capital Advisors LLC with notifications on news.

Account

Verdence Capital Advisors LLC Gilead Sciences, Inc. Transaction History